Abstract PS5-08-03: Denali-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with triple-negative breast cancer and other EGFR-expressing solid tumors with HLA-A*02 loss of heterozygosity (LOH)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: J. M. Specht, S. R. Punekar, M. Ulrickson, D. J. Wong, J. R. Hecht, M. Maus, P. M. Grierson, J. B. Sunwoo, J. R. Molina, D. G. Maloney, K. Spencer, H. E. Fuentes Bayne, M. Davila, S. P. Patel, B. Creelan, D. B. Zhen, J. Niu, D. C. Prasad, R. L. Marar, N. A. Bagegni, G. Palluconi, J. Lee, A. Mardiros, W. Bretzlaff, W. J. Langeberg, J. S. Welch, E. Ng, W. Y. Go, K. Kirtane, R. A. Shatsky
Institutions: University of Washington, Fred Hutch Cancer Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Banner MD Anderson Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Harvard University, Massachusetts General Hospital, Washington University in St. Louis, Stanford Medicine, Stanford University, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), Roswell Park Comprehensive Cancer Center, Moores Cancer Center, Moffitt Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129550893